Therapeutic collaboration of schizophrenic patients and a physician (the significance for therapeutic efficiency, the mechanisms of formation, and correction methods)
Abstract
Based on the data available in the literature and the results of his studies, the author analyzes one of the most important parts of the problem in the efficiency of treatment for schizophrenia, namely the quality of therapeutic collaboration (compliance) of patients and a physician. The paper gives data on the spread of low-quality therapeutic collaboration and discusses its reasons and impact on the efficiency of the therapeutic process. The efficiency of current psychopharmacotherapeutic methods aimed at optimizing the therapeutic collaboration is evaluated.
About the Author
D. S. Danilov
S.S. Korsakov Psychiatry Clinic, University Clinical Hospital Three;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Moscow
Russian Federation
Moscow
References
1. <div><p>Данилов Д.С. Терапия шизофрении (атипичные нейролептики и индивидуальная организация лечебного процесса). М.: Миклош, 2010;320 с.</p><p>Авруцкий Г.Я., Недува А.А. Лечение психически больных. М.: Медицина, 1988;528 с.</p><p>Прощенко И.В. Комплексное исследование больных параноидной формой шизофрении (клинико-социальные, патохимические и терапевтические аспекты). Автореф. дис. ... канд. мед. наук. М., 2008;20 с.</p><p>Cramer J.A., Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatric Services 1998;49(2):196-201.</p><p>Sair A., Bhui K., Hag S. et al. Improving treatment adherence among patients with chronic psychoses. Psychiat Bull 1998;22:77-81.</p><p>Lacro J.P., Dunn L.B., Dolder C.R. et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiat 2002;63(10):892-909.</p><p>Medication management approaches in psychiatry. Workbook - Draft, 2003;103 p.</p><p>Lieberman J., Stroup T., McEvoy J. et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. New Engl J Med 2005;353(12):1209-23.</p><p>Ascher-Svanum H., Zhu B., Faries D. et al. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. J Clin Psychiat 2006;67(7):1114-23.</p><p>Данилов Д.С., Тюльпин Ю.Г. Лечение шизофрении. М.: МИА, 2010;276 с.</p><p>Доказательная медицина (ежегодный справочник) Ч. 2. М.: МедиаСфера, 2003;241-72.</p><p>David A.S., Adams C. Depot antipsychotic medication in the treatment of patients with schizophrenia: (1) meta-review; (2) patient and nurse attitudes. Health Technol Asses 2001;34(5):1-61.</p><p>Walburn J., Gray R., Gournay K. et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Brit J Psychiat 2001;179(10):300-7.</p><p>Иванов С.В. Улучшение комплаентности больных шизофренией к терапии антипсихотиками. Психиатр и психофармакотер 2008;10(3):27-9.</p><p>Kinon B.J., Hill A.L., Liu H. et al. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia. Int J Neuropsychopharmacol 2003;6(2):97-102.</p><p>Markowitz J.S., DeVane C.L., Malcolm R.J. et al. Pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J Clin Pharmacol 2006;46(2):164-71.</p><p>Normann C., Schmauss M., Bakri N. et al. Initial treatment of severe acute psychosis with fast orally disintegrating risperidone tablets. Pharmacopsychiatry 2006;39(6):209-12.</p><p>Claxton A.J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23(8):1296-310.</p><p>Diaz E., Neuse E., Sullivan M.C. et al. Adherence to conventional and atypical antipsychotics after hospital discharge. J Clin Psychiat 2004;65(3):354-60.</p><p>Аведисова А.С., Бородин В.И. От нонкомплаенса к отказу от психофармакотерапии. Психиатр и психофармакотер 2005;7(6):316-8.</p><p>Бурковский Г.В., Левченко Е.В., Беркман А.М. Об исследованиях здоровья и качества жизни. Обозр психиатр и мед психол им. В.М. Бехтерева 2004;1:27-8.</p><p>Аведисова А.С., Ахапкин Р.В. Проблемы клинической оценки переносимости терапии психотропными препаратами. Психиатр и психофармакотер 2005;7(1):9-12.</p><p>Бугрова В.И. Несоблюдение режима внебольничной психофармакотерапии больными шизофренией: клинико-социальные и экономические аспекты. Дис. . канд. мед. наук. М., 2007;149 c.</p><p>Fenton W.S., Blyler C.R., Heinssen R.K. Determinants of medication compliance in schizophrenia: Empirical and clinical findings. Schizophrenia Bull 1997;23(4):637-51.</p><p>Boer R. Clinical study report. A single dose, randomized, two-period, two-treatment, two-sequence, crossover bioequivalence study on Risperidone 2 mg film-coated tablets (Novartis) versus Risperdal 2 mg film-coated tablets (Janssen-Cilag) in healthy volunteers. CEPHA s.r.o. study code №: CPA 141-01, Biochemie GmbH study code: RPD 63/01. Center for Pharmacology and Analysis Komenskeho, Czech Republic. August, 2002.</p><p>Каледа В.Г. Место рисполепта в современной психофармакотерапии. М.: НЦПЗ РАМН, 2003;37 с.</p><p>Информация о предельных отпускных ценах производителей и предельных розничных ценах на жизненно необходимые и важнейшие лекарственные препараты в субъектах Российской Федерации (по состоянию на 15 марта 2011 года). dravsite.nsf/va_WebPages/page_imp_medi-cine?OpenDocument.</p></div><br />
Review
For citations:
Danilov D.S. Therapeutic collaboration of schizophrenic patients and a physician (the significance for therapeutic efficiency, the mechanisms of formation, and correction methods). Neurology, Neuropsychiatry, Psychosomatics. 2011;3(2):17-24. (In Russ.) https://doi.org/10.14412/2074-2711-2011-142
Views: 518
Email this article 